Prof John Gribben and Prof Peter Hillmen at ASH 2014: New combination therapies provide great opportunities for CLL

Published on

Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL) that were presented at the 2014 American Society of Hematology (ASH) Annual Meeting.

New combination therapies provide new ways to manage patients with CLL. Will new combinations affect the duration of treatment and reduce the development of drug resistance? There is reference to a recent study of ABT-199 plus rituximab. Supported by an educational grant from Gilead Sciences Europe through Patient Empowerment Network

View more programs featuring

Join Our Community Register for Events Read Our Latest Blog

Page last updated on January 26, 2016